logo

For the Inventor, By the Inventor

Al-Ahsa, Saudi Arabia

Katharigatta N Venugopala

USPTO Granted Patents = 42 

Average Co-Inventor Count = 7.0

ph-index = 2

Forward Citations = 4(Granted Patents)


Location History:

  • Hofouf, SA (2022)
  • Al-Ahsa, SA (2023 - 2024)

Company Filing History:

goldMedal42 out of 2,421 
 
King Fahd University of Petroleum and Minerals
 patents

Years Active: 2022-2025

Loading Chart...
Areas of Expertise:
Antibacterial Agents
Anti-Tubercular Agents
Anti-Inflammatory Agents
Anticancer Agents
COX-2 Inhibitors
Larvicidal Agents
Adenosine Receptor Activity
Oxadiazole Derivatives
Pyrimidine Derivatives
Quinoline Derivatives
Thiazole Compounds
Fungal Agents
42 patents (USPTO):Explore Patents
1. 12297204 - 5-(substitutedphenyl)-7-thioxo-7,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione analogues as antibacterial agents (2025-05-13),
2. 12227516 - Selective COX-2 inhibition of 2-(substituted benzyl)-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-ones and 4-fluoro-n-(4-oxo-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-2-yl)benzamide as anti-inflammatory agents (2025-02-18),
3. 12227480 - 1-(2-(substituted phenyl)-2-oxoethyl)-4-methylpyridin-1-ium bromide as anti-tubercular agents (2025-02-18),
4. 12221450 - 5-(substitutedphenyl)-7-thioxo-7,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione analogues as antibacterial agents (2025-02-11),
5. 12215082 - (e)-1-(2-(4-substitutedphenyl)-2-oxoethyl)-4-((hydroxyimino)methyl)pyridinium bromides as antitubercular agents (2025-02-04),
6. 12202801 - 4-cyano-1-(2-oxo-2-(substituted phenyl) ethyl) pyridin-1-ium bromides as anti-tubercular agents (2025-01-21),
7. 12194029 - Ethyl-1-(substitutedbenzoyl)-5-methylpyrrolo[1,2-a]quinoline-3-carboxylates as anticancer agents (2025-01-14),
8. 12187733 - 5-(Substitutedphenyl)-7-Imino-7,8-Dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione analogues as anti-inflammatory agents (2025-01-07),
9. 12172973 - (E)-2-(3-Cyano-4-isobutoxyphenyl)-N'-(substituted benzylidene)-4-methylthiazole-5-carbohydrazides as anti-tubercular agents (2024-12-24),
10. 12145936 - 7-Imino-5-(1H-indol-3-yl)-1,3-substituted-7,8-dihdropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione as anti-inflammatory agents (2024-11-19),
11. 12145915 - (E)-2-(3-cyano-4-isobutoxyphenyl)-n'-(substituted benzylidene)-4-methylthiazole-5-carbohydrazides as anti-tubercular agents (2024-11-19),
12. 11998532 - Substituted 1,3,4-oxadiazole derivatives as anti-tubercular agents (2024-06-04),
13. 11987563 - 3-cyano 4,5-diphenyl furan-2-carboxamides as antitubercular agents (2024-05-21),
14. 11986476 - (6-methyl-4-substitutedphenyl-2-oxo/thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)(piperidin-1-yl)methanones as antitubercular agents (2024-05-21),
15. 11981674 - 7-isopropyl 1-ethyl/methyl 3-(substituted benzoyl)-2-substituted indolizine-1,7-dicarboxylates as larvicidal agents (2024-05-14),

Title: Inventor Katharigatta N Venugopala

Introduction: Katharigatta N Venugopala is a pioneering inventor based in Al-Ahsa, Saudi Arabia, known for her groundbreaking contributions to the field of innovations and patents.

Latest Patents: Katharigatta N Venugopala holds several recent patents in the areas of sustainable energy solutions and eco-friendly technologies, showcasing her commitment to environmental conservation.

Career Highlights: With a career spanning over two decades, Katharigatta N Venugopala has established herself as a leading figure in the innovation landscape, with a focus on creating solutions that positively impact society.

Collaborations: Throughout her career, Katharigatta N Venugopala has collaborated with various research institutions, universities, and companies to further develop and implement her inventions, fostering a culture of innovation and progress.

Conclusion: Katharigatta N Venugopala's dedication to pushing the boundaries of traditional thinking and her relentless pursuit of innovative solutions make her a true trailblazer in the world of inventions and patents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…